Drug Profile
RBL 001/RBL 002
Alternative Names: MERIT; RB0001; RB_0001; RBL-001/RBL-002; RBL-002/RBL-001Latest Information Update: 04 Dec 2021
Price :
$50
*
At a glance
- Originator BioNTech; Ribological
- Developer Ribological
- Class Cancer vaccines; RNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for phase-I development in Malignant-melanoma in Austria (Intralymphatic, Injection)
- 28 Jan 2020 No recent reports of development identified for phase-I development in Malignant-melanoma in Germany (Intralymphatic, Injection)
- 01 Oct 2019 BioNtech completes a phase I trial for Malignant melanoma (Late-stage disease) in Germany and Austria (NCT02035956)